CASI Pharmaceuticals (NASDAQ:CASI) versus Sanofi (NASDAQ:SNY) Head-To-Head Comparison

CASI Pharmaceuticals (NASDAQ:CASI) and Sanofi (NASDAQ:SNY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Earnings and Valuation

This table compares CASI Pharmaceuticals and Sanofi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85 million	0.10	-$39.26 million	($3.01)	-0.07
Sanofi	$49.35 billion	2.38	$8.84 billion	$2.02	24.01

Sanofi has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

Institutional & Insider Ownership

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares CASI Pharmaceuticals and Sanofi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Sanofi	8.70%	15.16%	8.48%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CASI Pharmaceuticals and Sanofi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1	0	0	0	1.00
Sanofi	0	12	8	1	2.48

Sanofi has a consensus price target of $53.00, suggesting a potential upside of 9.26%. Given Sanofi’s stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than CASI Pharmaceuticals.

Summary

Sanofi beats CASI Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About CASI Pharmaceuticals

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly for cancer and blood disorders. Its commercial and development activities have been centered largely on China. The company’s portfolio has included EVOMELA, a formulation of melphalan used in conditioning treatment for certain patients with multiple myeloma undergoing stem-cell transplantation. CASI has also pursued development and commercialization rights for additional oncology therapies, including CNCT19, an investigational CD19-directed CAR T-cell therapy.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.